The problem. The last decade has seen unprecedented progress in understanding the immune processes that drive atherosclerotic lesion initiation, maturation and complication. In particular, macrophages emerged as key cells that promote disease progression. If the number of inflammatory macrophages in plaque increases, atherosclerosis advances towards life-threatening complications. Plaque macrophages derive from circulating monocytes, which in turn arise from myeloid progenitors and hematopoietic stem cells. When released into circulation, monocytes follow chemokine gradients towards atherosclerotic plaque, where endothelial adhesion molecules aid their extravasation into the vessel wall. Once in plaque, inflammatory macrophages destabilize matrix via proteases and may die locally. Alternatively, if the local environment permits, macrophages may obtain less inflammatory phenotypes promoting cholesterol removal and tissue repair. These insights have been difficult to translate into clinically useful therapeutics, partly because broad anti-inflammatory therapy may compromise beneficial functions of immune cells and host defense. The goal. In this application, we aim to create a new class of macrophage-targeted atherosclerosis therapeutics using in vivo RNA interference (RNAi). We will design small interfering RNA (siRNA) targeting discrete proteins which are key decision nodes for macrophages' fate. We propose to interfere with the life cycle of macrophages with the goal to support inflammation resolution in atherosclerotic plaque. We will test the central hypothesis that RNAi can be harnessed to design precision therapeutics for inflammatory atherosclerosis. We will test this hypothesis by targeting proteins that are essential for macrophage birth (silencing transcription factors MTG16 and PU.1 that influence activity of hematopoietic stem cells and endothelial targets in the hematopoietic niche), migration (silencing chemokine receptors in monocytes and adhesion molecules in endothelial cells), maturation (silencing the M-CSF receptor essential for differentiation of monocytes into macrophages) and polarization (silencing the essential transcription factor IRF5 that gives rise to M1 macrophages with inflammatory functions). Innovation. We will use new nanomaterials for delivery to myeloid, progenitor and endothelial cells, newly and yet-to-be identified siRNA sequences, and target innovative biological targets important in the macrophage life cycle. Impact. We will develop new therapeutics to dampen inflammatory macrophage activity in the arterial wall. We will identify a winning therapeutic strategy in mice with post-MI acceleration of atherosclerosis, a scenario that simulates the vulnerable patient in need of aggressive therapeutic intervention. Our ultimate goal is to bring these materials into the clinic, improving the currently insufficient standard of care by enabling better secondary prevention of myocardial infarction and stroke.

Public Health Relevance

The proposed interdisciplinary research program will develop macrophage targeted in vivo RNAi for inflammatory atherosclerosis. Nanoparticle delivered siRNA will be used to silence macrophage-related proteins to therapeutically suppress peripheral tissue inflammation in plaque, lesion maturation, atherogenesis, and the risk of MI recurrence.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL125428-04
Application #
9844956
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Olive, Michelle
Project Start
2017-01-09
Project End
2020-12-31
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
4
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Hulsmans, Maarten; Sager, Hendrik B; Roh, Jason D et al. (2018) Cardiac macrophages promote diastolic dysfunction. J Exp Med 215:423-440
Cremer, Sebastian; Nahrendorf, Matthias (2018) Myeloid Cells Remodel the Mitral Valve. Circulation 137:2494-2496
Hulsmans, Maarten; Aguirre, Aaron D; Bonner, Matthew D et al. (2018) A Miniaturized, Programmable Pacemaker for Long-Term Studies in the Mouse. Circ Res 123:1208-1219
Vandoorne, Katrien; Rohde, David; Kim, Hye-Yeong et al. (2018) Imaging the Vascular Bone Marrow Niche During Inflammatory Stress. Circ Res 123:415-427
Nahrendorf, M (2018) Myeloid cells in cardiovascular organs. J Intern Med :
Vandoorne, Katrien; Nahrendorf, Matthias (2017) Multiparametric Imaging of Organ System Interfaces. Circ Cardiovasc Imaging 10:
Hulsmans, Maarten; Clauss, Sebastian; Xiao, Ling et al. (2017) Macrophages Facilitate Electrical Conduction in the Heart. Cell 169:510-522.e20